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the argument for selected HOX genes
being preferred targets of this class of
leukemogenic transcription factors. Once
the downstream targets of the vertebrate
HOX proteins are identified, both in
embryologic development and in leuke-
mogenesis, it should be possible to
expand on current models of HOX gene
involvement in the human leukemias,
hopefully yielding new targets for thera-
peutic intervention.
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Tumor cell breach of physiological barri-
ers defines the point in neoplastic growth
when medical intervention becomes infi-
nitely harder.The breach of such barriers
has often been associated with expres-
sion of one of more matrix metallopro-
teinases, a family of Zn-dependent
endopeptidases that collectively are
capable of cleaving virtually all extracel-
lular matrix substrates. In the July 11
issue of Cell, Hotary et al. (2003) demon-
strate that cancer cells rendered capable
of expressing a single proteinase, name-
ly the membrane bound matrix metallo-
proteinase-1 (MT1-MMP) (Sato et al.,
1994), acquire potent collagenolytic
activity that enables cell proliferation in a
three-dimensional collagen matrix or fib-
rin matrix and moreover enhances sub-
cutaneous growth of tumor cells in nude
mice. Remarkably, a similar effect is not
conferred by any of seven soluble matrix
metalloproteinases, including three
“classical” collagen-cleaving proteinases
(MMP-1, MMP-2, and MMP-13)
(Brinckerhoff and Matrisian, 2002;
Egeblad and Werb, 2002). Equally sur-
prising, the growth-promoting effect of
MT1-MMP was lost on planar, 2D sur-
faces or under circumstances where the
3D matrix is not degradable. The signifi-
cant difference between behavior in 2D
and 3D mirrors a previous observation
by Cukierman et al. (2001) on cell-matrix
adhesive properties.
Taken together, the observations in
the Hotary et al. paper have several
important implications. They support the
notion that pericellular interstitial col-
lagenolytic activity rests with a single
molecule—namely the tethered trans-
membrane collagen-cleaving member of
the MMP family (Brinckerhoff and
Matrisian, 2002; Egeblad and Werb,
2002) that alone is capable of conferring
collagen-degrading abilities to otherwise
incompetent cells. Although the predom-
inant paradigm for the role of MT1-MMP
in matrix degradation has been to act as
an activator of downstream-secreted
MMPs, Hotary et al. provide direct evi-
dence for an intrinsic collagenase activi-
ty of MT1-MMP. Whereas the lack of
impairment of collagen degradation in
several MMP knockout models could in
principle be ascribed to the obvious
redundancy of the system, MT1-MMP
depletion alone is sufficient to generate a
“collagen-indigestion” phenotype in the
mouse (Holmbeck et al., 1999).
Considering that MT1-MMP alone can
provide a tumor cell with invasiveness,
whereas secreted MMPs cannot, the
question arises whether additional teth-
ered MMPs can do it.
Hotary et al. moreover demonstrate
MT1-MMP: A collagenase essential for tumor cell invasive growth
The manuscript discussed in this preview describes that reconstituted three-dimensional extracellular matrices such as
fibrillar collagen and fibrin exert stringent territorial growth control on cells.The authors show that tumor cells are able to
escape the matrix-enforced growth control effect (entrapment) by pericellular proteolysis mediated by MT1-MMP, a mem-
brane bound matrix metalloproteinase capable of directly cleaving both type I collagen and fibrin but not by other, soluble
matrix metalloprotinases.These data convincingly demonstrate one way that tumor cells orchestrate proteolysis to invade
surrounding tissues.
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that the shift from a “noninvasive” to an
“invasive” phenotype in tumor cells can
be accomplished merely by expressing a
single molecule, MT1-MMP, and that this
ability to degrade a 3D matrix conveys a
growth advantage to tumor cells. Not
only does one single molecule appear to
suffice to confer invasiveness, but the
additional effect on cell proliferation mul-
tiplies the survival success of an estab-
lished transformed clone. Natural history
of human cancer provides suitable sce-
narios in which to fit these data into a
pathophysiological context. Melanoma
cells, for example, acquire the ability to
invade the underlying dermis before they
acquire the competence to establish sec-
ondary clonal growth in the dermis.
Ectopic expression of MT1-MMP in a
nontransformed epithelium induces a
significant proliferative response, which
may ultimately favor the selection of dys-
plastic and transformed phenotypes, as
per a conventional tumor promotion
effect (Ha et al., 2001). Hence, the potent
epigenetic control of cell growth exerted
by the extracellular matrix and highlight-
ed by the Hotary data and Ha et al.
extend to both normal and transformed
cells.
Implications of these findings for
cancer therapy are obvious. MT1-MMP
would be critical for the many steps in the
metastatic processes in which degrada-
tion of type I collagen is required, with
the noted exception, perhaps, of estab-
lishment of bone metastasis, the second
most common skeletal disease in adults
in the western world. Degradation of min-
eralized bone collagen employs not only
specialized cells, but also distinct
enzyme machineries. The pursuit of
MMP inhibition as a path to potent block-
ade of invasion and metastasis appears
attractive in the light of the emerging piv-
otal role of MT1-MMP in cancer invasion
demonstrated by Hotary et al.
Unfortunately, MMP intervention strate-
gies (Coussens et al., 2002) have met
with limited success, and severe side
effects (arthritic pain) have been report-
ed that can be accounted for, at least in
part, by impairment of collagen turnover
in the musculo-skeletal system.
Together, the data by Hotary et al.
point to MT1-MMP expression as a
potential critical feature, or step, in the
progressive development of an invasive
phenotype in natural tumors.The authors
clearly demonstrate that MT1-MMP
functions in this model system as an
intrinsic collagenolytic arm. In naturally
occurring tumors, MT1-MMP appears
more often to be induced in stromal cells
by the cancer cells. In either case, MT1-
MMP serves as a critical regulator of
both growth and dissemination of tumor
cells in a 3D matrix. Since MT1-MMP is
widely expressed in connective tissues,
and in tumor stroma, the relative role of
tumor-expressed MT1-MMP, and stro-
mally expressed MT1-MMP, in the con-
trol of tumor growth now becomes an
important question.
As clearly demonstrated by onco-
genes, determinants of tumor growth are
often identified long before their wider
role in physiology is recognized, and this
may be quite distinct from their role in
tumor biology. In the case of MT1-MMP,
an unusual overlap of the role exerted in
physiological process and in malignan-
cies is apparent. MT1-MMP-deficient
mice unraveled the paradox that disrup-
tion of anabolic processes was brought
about in the whole organism by the abla-
tion of the catabolic function of a pro-
tease. Inability to degrade collagen type I
in these animals compromises normal
growth on the organism, organ, and tis-
sue scale (Holmbeck et al., 1999). Within
the growth-impaired tissues of MT1-
MMP-deficient mice, cells remain
trapped within an undegradable collage-
nous matrix, in a way much reminiscent
of the entrapment of MT1-MMP-insuffi-
cient cancer cells in collagen or fibrin
gels. Normal cells and tumor cells may
thus use MT1-MMP for the same princi-
pal purpose, namely acquiring prolifera-
tive capabilities by remodeling of the
pericellular environment.
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